Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder (BOREAL)
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2016
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Urinary incontinence
- Focus Therapeutic Use
- Acronyms BOREAL
- Sponsors Allergan
- 21 Oct 2016 Status changed from recruiting to completed.
- 10 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016.
- 10 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2016.